^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Published date:
01/28/2020
Excerpt:
Recommendation 1.3. For patients with high PD-L1 expression (TPS ≥ 50%), non-SCC, and PS 0 to 1, clinicians may offer atezolizumab/carboplatin/paclitaxel/bevacizumab in the absence of contraindications to bevacizumab (Type: evidence based; Evidence quality: intermediate; Strength of recommendation: moderate).
DOI:
10.1200/JCO.19.03022
